- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06176716
Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride
December 17, 2023 updated by: Ahon Pharmaceutical Co., Ltd.
Phase I Clinical Study to Evaluate the Pharmacokinetics, Pharmacokinetics, and Safety of Intravenous Administration of Methoxyethyl Etomidate Hydrochloride for Injection in Subjects With Mild, Moderate, and Normal Hepatic Dysfunction.
A Phase I clinical study to compare the pharmacokinetics, pharmacokinetics, and safety of intravenous administration of methoxyetomidate hydrochloride for injection in subjects with mild hepatic insufficiency (Child-pugh A), moderate hepatic insufficiency (Child-Pugh B), and normal hepatic function.Main OBJECTIVE: To evaluate the pharmacokinetic characteristics of metoetomidate hydrochloride for injection in subjects with mild liver dysfunction (Child-Pugh A), moderate liver dysfunction (Child-Pugh B) and normal liver function, and to provide evidence for the clinical application of metoetomidate hydrochloride in patients with liver dysfunction.Secondary objective: To evaluate the safety and pharmacokinetics of metoetomidate hydrochloride for injection in subjects with mild hepatic insufficiency (Child-Pugh A), moderate hepatic insufficiency (Child-Pugh B), and normal hepatic dysfunction.Exploratory objective: To investigate and analyze the relationship between the pharmacokinetic index (MOAA/S, BIS) and the pharmacokinetic parameters of metoetomidate hydrochloride in subjects with different liver function states in this study.The CYP2C19 genotype of the subjects in the study was analyzed, and the influence of gene polymorphism on pharmacokinetic parameters of metoetomidate hydrochloride was explored according to the data of CYP2C19 genotype.The relationship between in vivo exposure to methoxyetomidate hydrochloride and liver injury was analyzed.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yanhua Ding, MD
- Phone Number: 130021 18186879768
- Email: dingyanhua2003@126.com
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- First Hospital of Jilin University
-
Contact:
- liyuan Zhao, MD
- Phone Number: 0431-88782013
- Email: kjkzhaoliyuan@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Sign informed consent before the test, and fully understand the test content, process and possible adverse reactions
- Be able to complete the study according to the requirements of the test plan 3 Subjects (including partners) were willing to voluntarily use effective contraception from screening until 6 months after the last study drug administration 4 Male or female subjects aged 18-70 years (including cut-off) 5 The weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg.Body Mass index (BMI) = weight (kg)/height 2 (m2), BMI in the range of 18-32 kg/m2 (including the threshold) 6 Blood pressure should be between 90-159/60-99 mmHg (including the cutoff);The heart rate should be between 55-100 beats/min (including the critical value);SpO2 suction air should be ≥95% 7 For subjects with normal liver function, normal or abnormal clinical laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) have no clinical significance 8 No potentially difficult airway (modified Markov score of grade I to II) 9 Subjects with normal liver function had no prior serious primary diseases of major organs, including but not limited to gastrointestinal, respiratory, kidney, liver, nervous, blood, endocrine, tumor, immune, mental, or cardiovascular and cerebrovascular diseases 10 Liver insufficiency with Child-Pugh grade A or B is liver insufficiency due to prior primary liver disease, including but not limited to non-alcoholic steatohepatitis, viral hepatitis (hepatitis B, hepatitis C), etc 11 Patients with liver dysfunction: have not taken medication within 4 weeks prior to screening, or require long-term treatment due to liver disease or other comorbidification and have a stable medication regimen (try to avoid CYP3A4 or CYP2C19 suppressors and strong inducers) 12 Patients with hepatic insufficiency: the glomerular filtration rate eGFR > 60mL/min/1.73m2
Exclusion Criteria:
- Average daily smoking in the 3 months prior to screening was greater than 5 cigarettes
- Patients with contraindications to deep sedation/general anesthesia or with a history of sedation/anesthesia accidents
- Subjects with a history of epilepsy
- Known to be allergic to methetomidate hydrochloride excipients for injection (mannitol, anhydrous disodium hydrogen phosphate);Or allergy (including drug allergy, allergic disease history, etc.)
- History of alcohol abuse in the 3 months prior to screening (average daily drinking > 2 units of alcohol (1 unit = 285 mL for beer, or 25 mL for spirits, or 100 mL for wine)
- History of drug abuse in the 3 months prior to the screening period, or use of benzodiazepines for more than 3 months
- Donate blood or plasma within 30 days prior to screening, or blood loss ≥200 mL, or plasmapheresis
- Subjects with normal liver function: Use of any prescription drug or Chinese herbal medicine in the 2 weeks prior to screening other than contraceptives, paracetamol, nonsteroidal anti-inflammatory drugs, local over-the-counter topical preparations
- Participants who participated in any drug clinical trials within 2 months prior to screening (Participants with liver dysfunction who participated in three or more drug clinical trials within 1 year prior to screening should also be excluded)
- ECG abnormalities were clinically significant and were judged by the investigator to be unsuitable for participation in the study [if tachycardia/bradycardia, degree II-III atrioventricular block, or prolonged QTcF interval requiring drug therapy (male ≥470 ms, female ≥480 ms),Corrected by Fridericia's formula) or otherwise clinically significant abnormalities determined by the clinician]
- Female subjects were lactating or had a positive blood pregnancy during the screening period or during the trial
- Subjects with normal liver function who tested positive for any of the indicators of hepatitis B surface antigen, hepatitis C antibody or hepatitis C core antigen, HIV antigen/antibody or syphilis antibody
- Patients with serious or clinically significant infections (such as respiratory or central nervous system infections), trauma, or major surgical operations within 4 weeks prior to screening
- People who were expected to have a tendency to surgery or hospitalization during the trial period
- People who have consumed any food or beverage containing alcohol (or positive breath test for alcohol), grapefruit/grapefruit juice, methylxanthine (e.g., coffee, tea, cola, chocolate), strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc., in the 1 day prior to administration
- Urine drug screening positive (morphine, methamphetamine, ketamine, cannabis, ecstasy)
- People who have used propofol, other sedative/narcotic drugs and/or opioid analgesics or combinations containing analgesics within 72 hours prior to administration
- Those who had any other factors deemed unsuitable by the investigator for participation in the study
- Patients with hepatic insufficiency: In addition to the primary liver disease itself, or any clinically significant clinical laboratory test abnormality and/or serious history that the investigator believes may affect the test results, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, immune, psychiatric, or cardiovascular and cerebrovascular diseases
- patients with liver dysfunction: alpha-fetoprotein > 100 ng/mL;Hemoglobin (Hgb) < 80 g/L, platelet ≤50×109/L;Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 times the upper limit of normal (ULN)
- Patients with liver insufficiency: patients with liver failure, or patients with hepatic encephalopathy, hepatocellular carcinoma (except Barcelona stage 0), esophageal variceal hemorrhage and other complications of cirrhosis that researchers consider inappropriate
- Patients with liver dysfunction: a history of liver transplantation
- Patients with liver dysfunction: HIV antigen/antibody screening positive;If syphilis antibody is positive, the rapid plasma rereaction hormone test (RPR) test should be added, and if RPR is also positive, it should be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Normal hepatic function
|
The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
|
Experimental: participants with mild hepatic impairment (Child-Pugh A)
|
The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
|
Experimental: participants with moderate hepatic impairment (Child-Pugh B)
|
The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters
Time Frame: up to 5 minutes after infusion
|
Cmax
|
up to 5 minutes after infusion
|
Pharmacokinetic parameters
Time Frame: immediately after infusion to infinite time
|
AUC0-inf
|
immediately after infusion to infinite time
|
Pharmacokinetic parameters
Time Frame: immediately after infusion to 24 hours after infusion
|
AUC0-t
|
immediately after infusion to 24 hours after infusion
|
Pharmacokinetic parameters
Time Frame: up to 6 hours after infusion
|
t1/2
|
up to 6 hours after infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic indicators
Time Frame: once within 10 minutes before dosing, once 1 minutes (±5seconds) after dosing, and once 2minutes (±30 seconds) after stopping dosing and during full wakefulness
|
MOAA/S score
|
once within 10 minutes before dosing, once 1 minutes (±5seconds) after dosing, and once 2minutes (±30 seconds) after stopping dosing and during full wakefulness
|
Pharmacodynamic indicators
Time Frame: 10 minutes before administration to full wakefulness, once every 1 minute
|
BIS score
|
10 minutes before administration to full wakefulness, once every 1 minute
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yanhua Ding, MD, The First Hospital of Jilin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 6, 2023
Primary Completion (Estimated)
March 30, 2024
Study Completion (Estimated)
April 30, 2024
Study Registration Dates
First Submitted
November 27, 2023
First Submitted That Met QC Criteria
December 17, 2023
First Posted (Estimated)
December 20, 2023
Study Record Updates
Last Update Posted (Estimated)
December 20, 2023
Last Update Submitted That Met QC Criteria
December 17, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET-26-HCl-CP-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Cardiox CorporationTerminatedHepatic Failure
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
-
National Taiwan University HospitalUnknownLiver Failure | Critical CareTaiwan
Clinical Trials on ET-26
-
NestléCompletedStool CompositionPhilippines
-
Menoufia UniversityAlexandria UniversityCompleted
-
Ahon Pharmaceutical Co., Ltd.Recruiting
-
Universidad de ZaragozaUniversity of ValladolidCompleted
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Conditions, MultipleUnited States
-
Centre Hospitalier Universitaire, AmiensRecruitingFunctional Magnetic Resonance Imaging | ASD | Social Cognition | Eye Tracking | Joint AttentionFrance
-
Vyaire MedicalM.D. Anderson Cancer CenterCompleted
-
Novartis PharmaceuticalsRecruiting
-
Institute of Hematology & Blood Diseases Hospital...EdiGene Inc.; The Affiliated Hospital Of Guizhou Medical University; Zunyi Medical...Active, not recruitingTransfusion Dependent Beta-ThalassaemiaChina